文献速递姑息放疗与转移瘤泌尿生殖与妇科肿瘤放疗放疗物理与技术

靶体积与剂量概念对前列腺癌脊柱转移SBRT结局的影响:欧洲多中心队列研究

Impact of target volume and dose concepts on the outcomes of prostate cancer patients treated with stereotactic body radiotherapy for spinal metastases - a European multicenter cohort study.
PubMed 文献 · Radiother Oncol · 2025-11-08

该研究回顾性分析2010—2024年19个欧洲中心213例前列腺癌脊柱骨转移患者(283个病灶)接受SBRT的结局。中位随访25.1个月,SIB概念及BED4≥100 Gy与PFS、BRFS改善相关,FFLR显著 favoring BED4≥100 Gy,OS无显著差异,不良事件率低(骨折率2.2%)。

要点

  • SIB概念与BED4≥100 Gy与PFS和BRFS改善正相关。
  • FFLR观察到显著差异, favoring BED4≥100 Gy。
  • OS在各剂量与靶体积概念间无显著差异。

核心结论

  • 前列腺癌脊柱骨转移SBRT是有效且耐受性良好的治疗。
  • BED与SIB概念的使用均与PFS和BRFS改善相关。

研究设计与样本

  • 回顾性多中心队列研究,纳入2010至2024年19个欧洲癌症中心的前列腺癌脊柱骨转移接受SBRT的患者。
  • 共评估213例患者、283个脊柱骨转移灶,中位随访25.1个月(范围1.4–77.2)。

主要发现

  • SIB概念下BED4≥100 Gy的1年/3年PFS为85.7%/73.9%,非SIB概念下BED4≥100 Gy为81.2%/45.5%。
  • SIB治疗的骨转移灶1年/3年BRFS为81.7%/68.4%(BED4≥100 Gy),非SIB为78.3%/43.6%(BED4≥100 Gy)。
  • OS在所评估的剂量与靶体积概念间无显著差异。
  • FFLR观察到显著差异, favoring BED4≥100 Gy。
  • 多因素分析中,GTVmean剂量的BED4和SIB概念均与PFS和BRFS正相关。

关键数值与推荐

  • SIB概念且BED4≥100 Gy时1年/3年PFS为85.7%/73.9%。
  • 非SIB概念且BED4≥100 Gy时1年/3年PFS为81.2%/45.5%。
  • SIB治疗骨转移灶且BED4≥100 Gy时1年/3年BRFS为81.7%/68.4%。
  • 非SIB且BED4≥100 Gy时1年/3年BRFS为78.3%/43.6%。
  • 不良事件中骨折发生率为2.2%。

临床怎么用

  • 对前列腺癌脊柱骨转移行SBRT时,可考虑采用SIB概念并达到BED4≥100 Gy以改善PFS和BRFS。
  • FFLR获益支持BED4≥100 Gy的剂量选择。
  • 该方案不良事件率低,骨折率2.2%,耐受性良好。

局限性

  • 为回顾性多中心队列研究,需前瞻性研究确认结果并进一步标准化SBRT概念。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: The importance of metastasis-directed radiotherapy is increasing in the management of oligometastatic prostate cancer. We evaluated different target volume and dose concepts for stereotactic body radiotherapy (SBRT) of spine bone metastases (BoM) from prostate cancer in a large European cohort. MATERIAL AND METHODS: Data of prostate cancer patients receiving SBRT for spine BoM between 2010 and 2024 at 19 European cancer centers were retrospectively collected. Treatment volumes and dose concepts were analyzed regarding their impact on overall survival (OS), freedom from local recurrence (FFLR), biochemical recurrence-free survival (BRFS), and progression-free survival (PFS). RESULTS: With a median follow-up of 25.1 months (range: 1.4-77.2), 213 patients with 283 spine BoM were evaluated. 1-/3-year PFS with simultaneously integrated boost (SIB) were 85.7 %/73.9 % (BED4 [Biologically effective dose with α/β-ratio = 4 Gy] ≥ 100 Gy) and for non-SIB concepts 81.2 %/45.5 % (BED4 ≥ 100 Gy), respectively. 1-/3-year BRFS for SIB-treated BoM amounted to 81.7 %/68.4 % (BED4 ≥ 100 Gy) and for non-SIB 78.3 %/43.6 % (BED4 ≥ 100 Gy). OS was not significantly different for the evaluated dose and target volume concepts. For FFLR a significant difference was observed favoring BED4 ≥ 100 Gy. In multivariable analysis, following factors were positively associated with both PFS and BRFS: BED4 for GTVmean dose and SIB concept. Adverse events were very low, with fracture rates of 2.2 %. CONCLUSION: This multicenter cohort analysis showed that SBRT of spine BoM from prostate cancer is an effective and well-tolerated treatment. Both BED and usage of a SIB concept were associated with improved PFS and BRFS. Prospective studies are needed to confirm these findings and further standardize SBRT concepts.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Seiler I, Schäfer S, von Wachter C, et al. Impact of target volume and dose concepts on the outcomes of prostate cancer patients treated with stereotactic body radiotherapy for spinal metastases - a European multicenter cohort study. Radiother Oncol. 2025. PMID: 41213475. doi:10.1016/j.radonc.2025.111276

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。